Department of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China.
Department of Gastrointestinal Surgery, Peking University Shenzhen Hospital, Shenzhen, 518036, Guangdong, China.
BMC Cancer. 2020 Jul 17;20(1):671. doi: 10.1186/s12885-020-07031-9.
To investigate whether there is a distinct difference in prognosis between hepatoid adenocarcinoma of the stomach (HAS) and non-hepatoid adenocarcinoma of the stomach (non-HAS) and whether HAS can benefit from radical surgery.
We retrospectively reviewed 722 patients with non-HAS and 75 patients with HAS who underwent radical gastrectomy between 3 November 2009 and 17 December 2018. Propensity score matching (PSM) analysis was used to eliminate the bias among the patients in our study. The relationships between gastric cancer type and overall survival (OS) were evaluated by the Kaplan-Meier method and Cox regression.
Our data demonstrate that there was no statistically significant difference in the OS between HAS and non-HAS {K-M, P = log rank (Mantel-Cox), (before PSM P = 0.397); (1:1 PSM P = 0.345); (1:2 PSM P = 0.195)}. Moreover, there were no significant differences in the 1-, 2-, or 3-year survival rates between patients with non-HAS and patients with HAS (before propensity matching, after 1:1 propensity matching, and after 1:2 propensity matching).
HAS was generally considered to be an aggressive gastric neoplasm, but its prognosis may not be as unsatisfactory as previously believed.
为了研究胃肝样腺癌（HAS）与非肝样腺癌（non-HAS）之间的预后是否存在显著差异，以及 HAS 是否能从根治性手术中获益。
我们回顾性分析了 2009 年 11 月 3 日至 2018 年 12 月 17 日期间接受根治性胃切除术的 722 例 non-HAS 患者和 75 例 HAS 患者。采用倾向评分匹配（PSM）分析消除研究中患者之间的偏倚。采用 Kaplan-Meier 法和 Cox 回归评估胃癌类型与总生存期（OS）的关系。
我们的数据表明，HAS 和 non-HAS 之间的 OS 无统计学差异{K-M，P=log rank（Mantel-Cox），（匹配前 PSM P=0.397）；（1:1 PSM P=0.345）；（1:2 PSM P=0.195）}。此外，non-HAS 患者和 HAS 患者的 1 年、2 年和 3 年生存率无显著差异（匹配前、1:1 倾向匹配后和 1:2 倾向匹配后）。
HAS 通常被认为是一种侵袭性胃肿瘤，但它的预后可能并不像以前认为的那样不理想。
